Autolus Therapeutics plc

Autolus Therapeutics plcverified

AUTL

Price:

$2.215

Market Cap:

$589.45M

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; a...[Read more]

Industry

Biotechnology

IPO Date

2018-06-22

Stock Exchange

NASDAQ

Ticker

AUTL

The Enterprise Value as of December 2024 (TTM) for Autolus Therapeutics plc (AUTL) is -15383857.00

According to Autolus Therapeutics plc’s latest financial reports and current stock price. The company's current Enterprise Value is -15383857.00. This represents a change of -102.38% compared to the average of 645.82M of the last 4 quarters.

Autolus Therapeutics plc (AUTL) Historical Enterprise Value (quarterly & annually)

How has AUTL Enterprise Value performed in the past?

The mean historical Enterprise Value of Autolus Therapeutics plc over the last ten years is 358.14M. The current -15383857.00 Enterprise Value has changed -529.55% with respect to the historical average. Over the past ten years (40 quarters), AUTL's Enterprise Value was at its highest in in the December 2018 quarter at 1.07B. The Enterprise Value was at its lowest in in the December 2022 quarter at -135541306.00.

Quarterly (TTM)
Annual

Average

358.14M

Median

334.40M

Minimum

-177692540.00

Maximum

933.59M

Autolus Therapeutics plc (AUTL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Autolus Therapeutics plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 274.36%

Maximum Annual Enterprise Value = 933.59M

Minimum Annual Increase = -625.39%

Minimum Annual Enterprise Value = -177692540.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023933.59M-625.39%
2022-177692540.00-309.60%
202184.78M-76.57%
2020361.79M-5.79%
2019384.04M-50.63%
2018777.83M274.36%
2017207.78M-34.40%
2016316.71M-5.29%

Autolus Therapeutics plc (AUTL) Average Enterprise Value

How has AUTL Enterprise Value performed in the past?

The current Enterprise Value of Autolus Therapeutics plc (AUTL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

280.22M

5-year avg

317.30M

10-year avg

358.14M

Autolus Therapeutics plc (AUTL) Enterprise Value vs. Peers

How is AUTL’s Enterprise Value compared to its peers?

Autolus Therapeutics plc’s Enterprise Value is less than Cullinan Oncology, Inc. (610.74M), less than Bolt Biotherapeutics, Inc. (28.33M), less than Day One Biopharmaceuticals, Inc. (851.52M), less than Lyra Therapeutics, Inc. (22.84M), less than Acumen Pharmaceuticals, Inc. (103.75M), less than X4 Pharmaceuticals, Inc. (84.30M), less than Inozyme Pharma, Inc. (208.51M), less than VectivBio Holding AG (848.58M), less than Terns Pharmaceuticals, Inc. (219.57M), less than Amylyx Pharmaceuticals, Inc. (206.29M), less than Ikena Oncology, Inc. (39.69M), less than Anebulo Pharmaceuticals, Inc. (37.88M), less than Celcuity Inc. (547.97M), less than MediciNova, Inc. (59.45M), less than Rezolute, Inc. (244.24M), less than Mirati Therapeutics, Inc. (3.91B), less than Apellis Pharmaceuticals, Inc. (4.18B),

Build a custom stock screener for Autolus Therapeutics plc (AUTL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Autolus Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Autolus Therapeutics plc (AUTL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Autolus Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Autolus Therapeutics plc's Enterprise Value?

What is the highest Enterprise Value for Autolus Therapeutics plc (AUTL)?

What is the 3-year average Enterprise Value for Autolus Therapeutics plc (AUTL)?

What is the 5-year average Enterprise Value for Autolus Therapeutics plc (AUTL)?

How does the current Enterprise Value for Autolus Therapeutics plc (AUTL) compare to its historical average?